

Supplementary table S1: Comparison of the persons participating in both phases with those who only attended phase 1

	Persons participating in both P1 and P2	%	Persons not participating in P2	%
Total	22,130	100%	7,924	100%
Sex				
Female	13,824	62.5%	4,438	56.0%
Male	8,306	37.5%	3,486	44.0%
Age groups				
18-29	1,491	6.7%	1,069	13.5%
30-39	2,774	12.5%	1,485	18.7%
40-49	6,700	30.3%	2,431	30.7%
50-59	6,049	27.3%	1,658	20.9%
60+	5,116	23.1%	1,281	16.2%
COVID in history				
Seronegative	11,352	51.3%	4,641	58.6%
Seropositive – no symptoms	5,597	25.3%	1,757	22.2%
Seropositive – with symptoms	5,181	23.4%	1,526	19.3%
BMI				
under 18.5	256	1.2%	85	1.1%
18.5-24.9	8,192	37.0%	2,791	35.2%
25-29.9	8,080	36.5%	2,360	29.8%
30 and more	4,802	21.7%	1,189	15.0%
missing	800	3.6%	1,499	18.9%
NCDs in history				
No	13,888	62.8%	6,563	82.8%
Yes	7,152	32.3%	539	6.8%
missing	1,090	4.9%	822	10.4%

Supplementary table S2: Overview of seroconversion by general population over time (04/2021-09/2021) - PHASE 2 - with adjustment for sensitivity and specificity of serological tests

N = 22,130	Total	Positive		Estimated seroprevalence in general population		Seroprevalence adjusted for sensitivity and specificity of serological tests	
		N	%	%	95% CI	Lower bound	Upper bound
SARS-CoV-2- & No vaccination	2,848	728	25.56%	23.97%	22.18-25.85%	20.19%	29.62%
SARS-CoV-2+ & No vaccination	4,799	4,367	91.00%	89.57%	88.33-90.70%	88.06%	100.00%
SARS-CoV-2- & With vaccination	7,495	7,285	97.20%	97.36%	96.72-97.88%	96.67%	100.00%
SARS-CoV-2+ & With vaccination	6,988	6,969	99.73%	99.81%	99.68-99.89%	99.70%	100.00%
Total	22,130	19,349	87.43%	84.37%	83.64-85.07%	83.25%	98.00%

SARS-CoV-2- = seronegative at phase 1 AND self-report of negative or not done PCR test between phase 1 and 2

SARS-CoV-2+ = seropositive at phase 1 OR self-report of positive PCR test between phase 1 and 2